Murine Macrophages Modulate Their Inflammatory Profile in Response to Gas Plasma-Inactivated Pancreatic Cancer Cells.
CAP
PDA6606
cold atmospheric pressure plasma
cold physical plasma
kINPen
metastasis
plasma medicine
tumor microenvironment (TME)
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
21 May 2021
21 May 2021
Historique:
received:
04
05
2021
revised:
17
05
2021
accepted:
19
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
Macrophages and immuno-modulation play a dominant role in the pathology of pancreatic cancer. Gas plasma is a technology recently suggested to demonstrate anticancer efficacy. To this end, two murine cell lines were employed to analyze the inflammatory consequences of plasma-treated pancreatic cancer cells (PDA) on macrophages using the kINPen plasma jet. Plasma treatment decreased the metabolic activity, viability, and migratory activity in an ROS- and treatment time-dependent manner in PDA cells in vitro. These results were confirmed in pancreatic tumors grown on chicken embryos in the TUM-CAM model (in ovo). PDA cells promote tumor-supporting M2 macrophage polarization and cluster formation. Plasma treatment of PDA cells abrogated this cluster formation with a mixed M1/M2 phenotype observed in such co-cultured macrophages. Multiplex chemokine and cytokine quantification showed a marked decrease of the neutrophil chemoattractant CXCL1, IL6, and the tumor growth supporting TGFβ and VEGF in plasma-treated compared to untreated co-culture settings. At the same time, macrophage-attractant CCL4 and MCP1 release were profoundly enhanced. These cellular and secretome data suggest that the plasma-inactivated PDA6606 cells modulate the inflammatory profile of murine RAW 264.7 macrophages favorably, which may support plasma cancer therapy.
Identifiants
pubmed: 34064000
pii: cancers13112525
doi: 10.3390/cancers13112525
pmc: PMC8196763
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Bundesministerium für Bildung und Forschung
ID : 03Z22DN11
Organisme : Bundesministerium für Bildung und Forschung
ID : 03Z22Di1
Références
Sci Rep. 2019 Mar 11;9(1):4099
pubmed: 30858524
Cancer Cell. 2018 Nov 12;34(5):757-774.e7
pubmed: 30423296
Mol Cancer Ther. 2002 Jan;1(3):161-7
pubmed: 12467210
Anticancer Agents Med Chem. 2018;18(6):824-831
pubmed: 29732979
Cancer Immunol Res. 2017 Mar;5(3):211-221
pubmed: 28159747
Biochem Biophys Res Commun. 2018 Mar 4;497(2):583-590
pubmed: 29462614
Environ Mol Mutagen. 2018 May;59(4):268-277
pubmed: 29417643
Br J Cancer. 2019 Jan;120(1):45-53
pubmed: 30413828
Cancers (Basel). 2019 Aug 23;11(9):
pubmed: 31450811
Cancer Cell. 2016 Jun 13;29(6):832-845
pubmed: 27265504
Int J Mol Sci. 2017 Apr 19;18(4):
pubmed: 28422070
Cancer Res. 2014 Sep 1;74(17):4706-19
pubmed: 25035397
Sci Rep. 2018 May 16;8(1):7736
pubmed: 29769633
Appl Phys Lett. 2010 Jun 14;96(24):243701
pubmed: 20628488
Ther Adv Med Oncol. 2018 Jul 20;10:1758835918786475
pubmed: 30046358
Arch Biochem Biophys. 2014 Mar 1;545:133-40
pubmed: 24486404
World J Oncol. 2019 Feb;10(1):10-27
pubmed: 30834048
PLoS One. 2012;7(12):e52653
pubmed: 23300736
Oncotarget. 2014 Apr 15;5(7):1869-84
pubmed: 24681847
Cancers (Basel). 2020 Nov 30;12(12):
pubmed: 33265951
Cell Cycle. 2010 Feb 15;9(4):662-9
pubmed: 20139725
J Immunother Cancer. 2019 May 28;7(1):140
pubmed: 31138333
Int J Oncol. 2015 Nov;47(5):1655-62
pubmed: 26351772
Clin Cancer Res. 2013 Jul 1;19(13):3404-15
pubmed: 23653148
Biochem J. 2012 Jan 15;441(2):541-52
pubmed: 22187935
Pancreatology. 2013 Sep-Oct;13(5):508-16
pubmed: 24075516
Int J Mol Sci. 2021 Apr 06;22(7):
pubmed: 33917526
Gut. 2007 Jan;56(1):107-14
pubmed: 16891358
J Biol Chem. 2007 Jan 12;282(2):1183-92
pubmed: 17105724
Anticancer Res. 2019 Jun;39(6):2871-2882
pubmed: 31177125
PLoS One. 2016 Sep 01;11(9):e0160667
pubmed: 27584003
Front Immunol. 2017 Feb 06;8:86
pubmed: 28220123
Semin Immunol. 2014 Feb;26(1):80-7
pubmed: 24572992
Ann Surg Oncol. 2018 Jan;25(1):299-307
pubmed: 29139022
Oxid Med Cell Longev. 2019 Sep 19;2019:8535163
pubmed: 31641425
Sci Rep. 2017 Aug 16;7(1):8319
pubmed: 28814809
Cancers (Basel). 2019 Oct 19;11(10):
pubmed: 31635070
Nature. 2016 Apr 14;532(7598):245-9
pubmed: 27049944
Free Radic Biol Med. 2021 May 1;167:12-28
pubmed: 33711420
Oncoimmunology. 2017 Nov 13;7(2):e1393596
pubmed: 29308326
Int J Mol Sci. 2018 Nov 13;19(11):
pubmed: 30428588
Int J Mol Sci. 2020 Feb 18;21(4):
pubmed: 32085661
J Leukoc Biol. 2016 Oct;100(4):791-799
pubmed: 26992432
Proc Natl Acad Sci U S A. 2009 Oct 13;106(41):17475-80
pubmed: 19805133
Lancet Oncol. 2004 Apr;5(4):254-8
pubmed: 15050959
Mol Cancer Ther. 2008 Apr;7(4):829-40
pubmed: 18413796
Exp Dermatol. 2013 Apr;22(4):284-9
pubmed: 23528215
Adv Sci (Weinh). 2021 Mar 08;8(10):2003395
pubmed: 34026437
Front Immunol. 2018 Apr 05;9:527
pubmed: 29675018
Proc Natl Acad Sci U S A. 2016 May 10;113(19):E2646-54
pubmed: 27091975
J Exp Clin Cancer Res. 2016 Feb 04;35:27
pubmed: 26847351
Immunity. 2018 Jul 17;49(1):178-193.e7
pubmed: 29958801
Int J Mol Sci. 2018 Aug 16;19(8):
pubmed: 30115896
Curr Pharm Des. 2012;18(17):2416-9
pubmed: 22372505
Cell Biosci. 2017 Aug 7;7:39
pubmed: 28794854
Biol Chem. 2018 Dec 19;400(1):63-75
pubmed: 30030959
Antioxidants (Basel). 2020 Apr 16;9(4):
pubmed: 32316245
Oxid Med Cell Longev. 2019 Oct 8;2019:9062098
pubmed: 31687089
Int J Cancer. 2014 Aug 15;135(4):843-61
pubmed: 24458546
Mol Cancer. 2018 Jul 30;17(1):108
pubmed: 30060755
Cancers (Basel). 2021 Jan 23;13(3):
pubmed: 33498676
Acta Gastroenterol Belg. 2020 Apr-Jun;83(2):295-299
pubmed: 32603049
J Surg Res. 2011 May 15;167(2):e211-9
pubmed: 19765725
Int J Mol Sci. 2021 Feb 03;22(4):
pubmed: 33546421
Free Radic Biol Med. 2021 Apr;166:187-200
pubmed: 33636332
Oncol Rep. 2018 Apr;39(4):1573-1582
pubmed: 29484419
J Mol Med (Berl). 2008 May;86(5):523-9
pubmed: 18311471
Cancer Res. 2017 Dec 1;77(23):6667-6678
pubmed: 28993412
Cancer Lett. 2014 Apr 10;345(2):157-63
pubmed: 23879960
Anticancer Res. 2018 Oct;38(10):5655-5663
pubmed: 30275184
Curr Opin Cell Biol. 2005 Oct;17(5):559-64
pubmed: 16098726
Biomaterials. 2018 May;163:185-197
pubmed: 29477032
PLoS One. 2013;8(2):e54841
pubmed: 23418431
Cancers (Basel). 2020 Jan 02;12(1):
pubmed: 31906582
Oral Dis. 2020 Oct 27;:
pubmed: 33107655
Expert Opin Ther Targets. 2011 Jul;15(7):817-28
pubmed: 21391891
J Phys D Appl Phys. 2019 Oct 22;52(42):
pubmed: 31485083
Oncogenesis. 2019 Jan 18;8(2):8
pubmed: 30659170
Adv Sci (Weinh). 2020 Mar 30;7(10):1903438
pubmed: 32440479
Br J Cancer. 2013 Mar 5;108(4):914-23
pubmed: 23385730
Ann Surg Oncol. 2008 Jun;15(6):1651-60
pubmed: 18351300
Acta Biochim Biophys Sin (Shanghai). 2018 Jan 1;50(1):121-132
pubmed: 29190313
Cancer Sci. 2008 Sep;99(9):1720-5
pubmed: 18564137
Cancer Res. 2007 Jan 1;67(1):139-48
pubmed: 17210693
Cell. 2012 Jul 6;150(1):165-78
pubmed: 22770218
Oncoimmunology. 2020 Dec 29;10(1):1859731
pubmed: 33457077
Hepatobiliary Pancreat Dis Int. 2014 Aug;13(4):371-80
pubmed: 25100121
Cancers (Basel). 2021 Feb 02;13(3):
pubmed: 33540720
Redox Biol. 2021 Jul;43:101968
pubmed: 33895486
Clin Cancer Res. 1997 Aug;3(8):1309-16
pubmed: 9815813
Int J Cancer. 2015 Sep 1;137(5):1035-46
pubmed: 25604508
Cancer Res. 2020 Mar 1;80(5):1088-1101
pubmed: 31915130
Oncotarget. 2016 Aug 2;7(31):50735-50754
pubmed: 27191744
Sci Rep. 2020 Mar 25;10(1):5420
pubmed: 32214219
Theranostics. 2019 Jun 2;9(12):3659-3673
pubmed: 31281505